Boston, MA 08/25/2014 (wallstreetpr) – Aastrom Biosciences Inc (NASDAQ:ASTM) announced that results of its two Phase 2a trials are published in the journal. The two trials results are of Phase 2a Catheter-DCM Study and IMPACT-DCM study. The phase 2a studies are clinical studies of ixmyelocel-T that is used to treat the advanced heart failure in patients suffering from Ischemic Dilated Cardiomyopathy The results of studies are positive as they reduce the chances of major adverse cardiovascular events in ischemic DCM patients.
Ixmyelocel-T
Ixmyelocel-T is a treatment therapy that uses patient’s bone marrow. Aastrom Biosciences Inc (NASDAQ:ASTM) has got highly automated and fully closed cell processing system that uses the bone marrow to create the multicellular therapy treatment. The objective is to enhance the number of mesenchymal stromal cells and activate macrophages. They are crucial for the growth of anti-inflammatory factors that in turn works for repairing the damaged tissues.
The open-label studies
Aastrom Biosciences Inc (NASDAQ:ASTM) conducted two distinct open-label studies. In all, 61 patients were selected out of which 59 were treated with the standard care. The patients who were given the treatment of ixmyelocel-T showed fewer events of MACE as compared to the control patients. Also, the ischemic DCM patients showed an improvement in the other symptoms.
The achievement
The publication of results in a peer-reviewed journal is an achievement for Aastrom. It validates the results of the study and indicates a positive development in multicellular therapy treatment. Aastrom Biosciences Inc (NASDAQ:ASTM) is looking to conduct a larger, Phase 2b trial which will have a higher number of enrolled patients. The results show a promising future in the use of ixmyelocel-T for treating patients suffering from ischemic dilated Cardiomyopathy. As of now, the patients have to compromise a lot as there are limited treatment options available in the industry. Aastrom is positive on the development program and will make sure to speed it up to reach the final stage of clinical research.
